Morning Trend | Gilead Sciences increases defensive capital, can the support level reversal be staged?
Gilead Sciences (GILD.US) fluctuated around the key support level of 116.88 during intraday trading on January 15, with limited short-term trading activity. However, defensive institutional investors have been quietly increasing their positions. Although short-selling pressure has not been alleviated, the bullish front has held quite firmly. Recently, there have been no significant positive developments in the pharmaceutical sector and limited capital inflow, with only sporadic rotations within the industry, leading to overall cautious sentiment. Nevertheless, blue-chip defensive funds have shown considerable resilience. Currently, key indicators at the daily level continue to suppress rebounds, and under high pressure, trading volume is gradually shrinking, with no significant signs of major players exiting. The market has mitigated the risk of a "collapse wave." What everyone is most concerned about now is whether 116.88 can turn from defense to offense, becoming the starting point for the next wave of small-scale rebounds or rotations. In the community, there have been signs of capital quietly flowing back in recent days, with large orders occasionally appearing during intraday fluctuations, linking to the pharmaceutical brother sectors. Funds are poised to ignite sentiment, especially as the earnings report window approaches. If there are sudden positive developments in the industry or individual stocks rebound after a crash, a "defensive rebound" window may likely emerge in the short term. The operational suggestion is to closely monitor the support line, actively follow up on significant volume fluctuations, and conversely, remain cautiously observant if there is a continuous decrease in volume upon breaking key levels. Overall, Gilead Sciences has become an important haven for market risk-averse funds, with a core focus on capital flow and the strength of support
Technical Forecast·
